Bellicum Pharmaceuticals, Inc. (“Bellicum”) is a biopharmaceutical company that has developed novel cellular immunotherapies for various forms of cancer.
Company profile
Ticker
BLCM
Exchange
Website
CEO
Richard Fair
Employees
Location
Fiscal year end
Industry (SIC)
Former names
BELLICUM PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Bellicum Pharma Limited • Bellicum Pharma GmbH ...
BLCM stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Mar 24
EFFECT
Notice of effectiveness
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
POS AM
Prospectus update (post-effective amendment)
23 Feb 24
POS AM
Prospectus update (post-effective amendment)
23 Feb 24
Transcripts
BLCM
Earnings call transcript
2020 Q4
31 Mar 21
BLCM
Earnings call transcript
2020 Q2
6 Aug 20
BLCM
Earnings call transcript
2019 Q4
12 Mar 20
BLCM
Earnings call transcript
2019 Q3
6 Nov 19
BLCM
Earnings call transcript
2018 Q4
12 Mar 19
BLCM
Earnings call transcript
2018 Q2
7 Aug 18
BLCM
Earnings call transcript
2017 Q4
13 Mar 18
Latest ownership filings
SC 13G/A
Ikarian Capital, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
BAKER BROS. ADVISORS LP
24 Nov 23
4
JULIAN BAKER
24 Nov 23
SC 13D
BAKER BROS. ADVISORS LP
5 May 23
3
JULIAN BAKER
5 May 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Ikarian Capital, LLC
14 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4/A
Reid M Huber
20 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm | 5.91 mm |
Cash burn (monthly) | 500.33 k | 1.90 mm | 257.67 k | 1.99 mm | 505.33 k | 1.90 mm |
Cash used (since last report) | 3.40 mm | 12.96 mm | 1.75 mm | 13.51 mm | 3.44 mm | 12.96 mm |
Cash remaining | 2.50 mm | -7.05 mm | 4.16 mm | -7.60 mm | 2.47 mm | -7.05 mm |
Runway (months of cash) | 5.0 | -3.7 | 16.1 | -3.8 | 4.9 | -3.7 |
Institutional ownership, Q2 2023
27.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 22 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.65 mm |
Total shares | 2.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 2.20 mm | $0.00 |
Boxer Capital | 450.00 k | $167.00 k |
National Asset Management | 11.42 k | $4.23 mm |
Tekla Capital Management | 6.00 k | $2.22 mm |
Princeton Global Asset Management | 100.00 | $37.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Nov 23 | Baker Bros. Advisors | Common Stock | Acquire X | Yes | No | 0.0001 | 1,941,607 | 194.16 | 2,168,818 | |
22 Nov 23 | Baker Bros. Advisors | Common Stock | Acquire X | Yes | No | 0.0001 | 174,742 | 17.47 | 196,654 | |
22 Nov 23 | Baker Bros. Advisors | Warrants Common Stock | Dispose X | Yes | No | 0.0001 | 1,941,607 | 194.16 | 14,217,844 | |
22 Nov 23 | Baker Bros. Advisors | Warrants Common Stock | Dispose X | Yes | No | 0.0001 | 174,742 | 17.47 | 1,287,987 | |
3 Jan 23 | Klimovsky Judith V | Common Stock | Option exercise | Acquire M | No | No | 0 | 60,414 | 0.00 | 110,098 |
3 Jan 23 | Huber Reid M | Common Stock | Option exercise | Acquire M | No | No | 0 | 87,196 | 0.00 | 153,179 |
3 Jan 23 | Stonehouse Jon P | Common Stock | Option exercise | Acquire M | No | No | 0 | 121,452 | 0.00 | 204,086 |